NCT06140953

Benefits of Trimetazidine in MASLD Patients

Evaluation of Potential Benefits of Trimetazidine in the Management of Patients With Metabolic Associated Steatotic Liver Disease (MASLD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD

Detailed description

the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease

Conditions

• Metabolic Associated Fatty Liver Disease

Interventions

Type	Name	Description
DRUG	Trimetazidine	trimetazidine at dose 20 mg three times daily to be taken by intervention group
DRUG	Conventional therapy	conventional therapy
DRUG	Placebo	placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only

Timeline

• Start date: 2023-12-10
• Primary completion: 2024-06-01
• Completion: 2024-11-30
• First posted: 2023-11-21
• Last updated: 2025-07-11

Locations

1 site across 1 country: Egypt